BioNTech SEBNTX +3.86%62 Days Inventory is 137.98 as of Mar. 2026, which is 4% above its 10-year median of 132.93. GuruFocus rates BNTX with a GF Score™ of 62/100 and a GF Value™ of $88.05 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 638 Biotechnology companies, BioNTech SE ranks better than 71.16% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). BioNTech SE's Average Total Inventories for the
three
months ended in Mar. 2026 was $125 Mil. BioNTech SE's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $83 Mil.
Hence, BioNTech SE's Days Inventory for the
three
months ended in Mar. 2026 was 137.98.
The historical rank and industry rank for BioNTech SE's Days Inventory or its related term are showing as below:
BNTX'
s Days Inventory Range Over the Past 10 Years
Min: 35.82 Med: 132.93 Max: 238.77
Current: 104.85
During the past 10 years, BioNTech SE's highest Days Inventory was 238.77. The lowest was 35.82. And the median was 132.93.
BNTX's Days Inventory is ranked better than 71.16% of 638
companies
in the Biotechnology industry
Industry Median: 183.875
vs BNTX: 104.85
BioNTech SE's Days Inventory
declined
from Mar. 2025 (287.90) to Mar. 2026 (137.98).
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioNTech SE's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.66.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioNTech SE's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.91.
BioNTech SE (NAS:BNTX) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
BioNTech SE's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioNTech SE's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
BioNTech SE Days Inventory Related Terms
BioNTech SE Days Inventory Historical Data
* Premium members only.
The historical data trend for BioNTech SE's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BNTX vs INCY, INSM, ROIV: Days Inventory Comparison
For the Biotechnology subindustry, BioNTech SE's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's Days Inventory distribution charts can be found below:
* The bar in red indicates where BioNTech SE's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE (BNTX) has a Days Inventory of 137.98 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BioNTech SE and its competitors. This is near median its historical median of 132.93. Over the past decade, BioNTech SE's Days Inventory has ranged from 35.82 to 238.77. According to the industry distribution chart, BioNTech SE ranks #184 out of 638 companies in the Biotechnology industry, placing it in the top 28.8%.
Is BioNTech SE's Days Inventory too high?
BioNTech SE's current Days Inventory of 137.98 is near median its 10-year median of 132.93. Over the past 10 years, this metric has ranged from a low of 35.82 to a high of 238.77. The Biotechnology industry median Days Inventory is 183.88. BioNTech SE's value of 137.98 is 25% below this industry median. Based on the distribution chart, BioNTech SE ranks #184 out of 638 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Days Inventory compare to INCY and INSM?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #184 out of 638 companies for Days Inventory. This puts BioNTech SE in the upper half of its industry. The industry median Days Inventory is 183.88. BioNTech SE's value of 137.98 is 25% below this benchmark. Historically, BioNTech SE's own Days Inventory has ranged from 35.82 to 238.77 over the past decade. While the company's 10-year median is 132.93 vs. the industry median of 183.88, BioNTech SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNTech SE's current Days Inventory of 137.98 is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BioNTech SE and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNTech SE's current Days Inventory is 137.98, which is near median its own 10-year median of 132.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BNTX) is currently considered Modestly Overvalued. The stock's GF Value™ is $88.05, compared to a current price of $97.55 — trading 10.8% above its estimated fair value. The current Days Inventory is 137.98, which is near median its 10-year median of 132.93 and 25% below the Biotechnology industry median of 183.88. BioNTech SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For BioNTech SE (BNTX), the current Days Inventory is 137.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BNTX) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of $97.55 is trading 10.8% above its estimated GF Value™ of $88.05.
GuruFocus considers BioNTech SE to be Modestly Overvalued.
Key valuation signals for BNTX:
Days Inventory: 137.98 (near median its 10-year median of 132.93)
GF Value™: $88.05 vs. price of $97.55 (10.8% above fair value)
Industry Position: 25% below the Biotechnology median (#184 of 638)
No single metric tells the full story. See the BNTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score
Get the complete analysis for BNTX
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNTX has been successfully added to your 
